

## Lipocine to Present at 28th Annual Roth Conference

SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) --[Lipocine Inc.](#) (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 28<sup>th</sup> Annual Roth Conference on Tuesday, March 15, 2016 at 8:00 a.m. PT.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the Lipocine website, [www.lipocine.com](http://www.lipocine.com). Please log on through Lipocine's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on Lipocine's website for 90 days following the presentation.

### About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. LPCN 1021, an oral testosterone replacement therapy product candidate, demonstrated positive efficacy and safety results in Phase 3 testing and has a New Drug Application under review with the FDA. LPCN 1111, a next-generation oral testosterone replacement therapy product with once daily dosing, is currently in Phase 2 testing. LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate product indicated for the prevention of recurrent preterm birth, is currently in Phase 1 testing. For more information, please visit [www.lipocine.com](http://www.lipocine.com).

### Forward-Looking Statements

This release contains "forward looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts relating to Lipocine's common stock and preferred stock, the FDA review process relating to our product candidates and the outcome of such process, clinical trials, the potential uses and benefits of our product candidates, product development and commercialization efforts and the projected timing and outcome of regulatory filings and actions. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks related to our products, expected product benefits, clinical and regulatory expectations and plans, regulatory developments and requirements, risks related to the FDA's review of our NDA for LPCN 1021, the receipt of regulatory approvals, the results of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, the risks related to market conditions for Lipocine's common stock and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at [www.sec.gov](http://www.sec.gov). Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

### CONTACT:

Morgan Brown  
Executive Vice President & Chief Financial Officer  
Phone: (801) 994-7383  
[mb@lipocine.com](mailto:mb@lipocine.com)

Investors:  
John Woolford  
Phone: (443) 213-0500  
[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)

Media:  
Heather Anderson  
Phone: (980) 938-0260  
[handerson@6degreespr.com](mailto:handerson@6degreespr.com)

---

<https://ir.lipocine.com/Lipocine-to-Present-at-28th-Annual-Roth-Conference>